Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Zachary Scott Wallace, M.D.

Co-Author

This page shows the publications co-authored by Zachary Wallace and Naomi Patel.
Connection Strength

5.958
  1. COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study. medRxiv. 2021 Aug 09.
    View in: PubMed
    Score: 0.978
  2. Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by Shanoj et al. Ann Rheum Dis. 2021 Mar 10.
    View in: PubMed
    Score: 0.475
  3. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease. Ann Rheum Dis. 2021 Jan 12.
    View in: PubMed
    Score: 0.470
  4. Management of primary vasculitides with biologic and novel small molecule medications. Curr Opin Rheumatol. 2021 01; 33(1):8-14.
    View in: PubMed
    Score: 0.469
  5. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis. 2021 05; 80(5):660-666.
    View in: PubMed
    Score: 0.466
  6. The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. Ann Rheum Dis. 2021 02; 80(2):274-276.
    View in: PubMed
    Score: 0.455
  7. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques et al. Ann Rheum Dis. 2020 Jul 13.
    View in: PubMed
    Score: 0.454
  8. Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani et al. Ann Rheum Dis. 2020 Jun 25.
    View in: PubMed
    Score: 0.452
  9. Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito et al and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao et al. Ann Rheum Dis. 2021 05; 80(5):e64.
    View in: PubMed
    Score: 0.451
  10. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. Ann Rheum Dis. 2020 09; 79(9):1156-1162.
    View in: PubMed
    Score: 0.450
  11. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. Ann Rheum Dis. 2021 Sep 06.
    View in: PubMed
    Score: 0.246
  12. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
    View in: PubMed
    Score: 0.118
  13. An 80-Year-Old Man With Fevers, Altered Mental Status, and Joint Effusions. Arthritis Care Res (Hoboken). 2020 03; 72(3):293-300.
    View in: PubMed
    Score: 0.111
  14. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open. 2021 10 01; 4(10):e2129639.
    View in: PubMed
    Score: 0.062
  15. COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. J Rheumatol. 2021 Sep 01.
    View in: PubMed
    Score: 0.061
  16. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2021 Aug 01.
    View in: PubMed
    Score: 0.061
  17. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
    View in: PubMed
    Score: 0.060
  18. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. Lancet Rheumatol. 2021 Sep; 3(9):e638-e647.
    View in: PubMed
    Score: 0.060
  19. Incident systemic rheumatic disease following COVID-19. Lancet Rheumatol. 2021 Jun; 3(6):e402-e404.
    View in: PubMed
    Score: 0.060
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.